AAAAAA

   
Results: 1-14 |
Results: 14
The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women
Authors: Minkoff, H Ahdieh, L Massad, LS Anastos, K Watts, DH Melnick, S Muderspach, L Burk, R Palefsky, J
Citation: H. Minkoff et al., The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women, AIDS, 15(16), 2001, pp. 2157-2164
Maternal therapy for HIV in pregnancy
Authors: Watts, DH
Citation: Dh. Watts, Maternal therapy for HIV in pregnancy, CLIN O GYNE, 44(2), 2001, pp. 182-197
Hormonal levels among HIV-1-seropositive women compared with high-risk HIV-seronegative women during the menstrual cycle
Authors: Cu-Uvin, S Wright, DJ Anderson, D Kovacs, A Watts, DH Cohn, J Landay, A Reichelderfer, PS
Citation: S. Cu-uvin et al., Hormonal levels among HIV-1-seropositive women compared with high-risk HIV-seronegative women during the menstrual cycle, J WOMEN H G, 9(8), 2000, pp. 857-863
1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
Authors: Masur, H Kaplan, JE Holmes, KK Alston, BL Ampel, N Anderson, JR Baker, AC Barr, D Bartlett, JG Bennett, JE Benson, CA Bozzette, SA Chaisson, RE Crumpacker, CS Currier, JS Deyton, L Drew, WL Duncan, WR Eisinger, RW El-Sadr, W Feinberg, J Freedberg, KA Furrer, H Gnann, JW Goldberger, MJ Goldie, S Goosby, EP Gross, PA Hafner, R Havlir, D Hooton, TM Jabs, DA Jacobson, MA Janoff, E Kitahata, M Kovacs, JV Leport, C Levin, MJ Lopez, JC Marco, M Mayers, DL Melnick, DA Mofenson, LM Montaner, JSG Moore, R Neaton, J Nelson, C O'Neill, JF Palefsky, J Pau, A Phair, JP Piscitelli, S Polis, MA Quinn, TC Reiss, P Rimland, D Sears, CL Seeff, L Sepkowitz, KA Slama, TG Sloand, EM Spector, SA Thomas, DL Van Dyke, RB Watts, DH Wheat, LJ Whitcup, SM Williams, P Wright, TC Castro, KG DeCock, KM Dowell, SF Dworkin, MS Dykewicz, C Ellerbrock, T Hajjeh, R Holmberg, S Holtgrave, DR Jaffe, HW Jones, JL Juranek, DD Mast, E Navin, T Pellett, PE Reeves, WC Stewart, JA Villarino, ME
Citation: H. Masur et al., 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus, CLIN INF D, 30, 2000, pp. S29-S65
Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine
Authors: Lambert, JS Watts, DH Mofenson, L Stiehm, ER Harris, DR Bethel, J Whitehouse, J Jimenez, E Gandia, J Scott, G O'Sullivan, MJ Kovacs, A Stek, A Shearer, WT Hammill, H van Dyke, R Maupin, R Silio, M Fowler, MG
Citation: Js. Lambert et al., Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine, AIDS, 14(10), 2000, pp. 1389-1399
Maternal and neonatal outcomes after induction of labor without an identified indication
Authors: Dublin, S Lydon-Rochelle, M Kaplan, RC Watts, DH Critchlow, CW
Citation: S. Dublin et al., Maternal and neonatal outcomes after induction of labor without an identified indication, AM J OBST G, 183(4), 2000, pp. 986-994
Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of <= 500/mu L
Authors: Watts, DH Lambert, JS Stiehm, ER Bethel, J Whitehouse, J Fowler, MG Read, J
Citation: Dh. Watts et al., Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of <= 500/mu L, AM J OBST G, 183(1), 2000, pp. 100-107
Comparison of gynecologic history and laboratory results in HIV-positive women with CD4(+) lymphocyte counts between 200 and 500 cells/mu l and below100 cells/mu l
Authors: Watts, DH Spino, C Zaborski, L Katzenstein, D Hammer, S Benson, C
Citation: Dh. Watts et al., Comparison of gynecologic history and laboratory results in HIV-positive women with CD4(+) lymphocyte counts between 200 and 500 cells/mu l and below100 cells/mu l, J ACQ IMM D, 20(5), 1999, pp. 455-462
Pregnant adolescents in chemical dependency treatment - Description and outcomes
Authors: Farrow, JA Watts, DH Krohn, MA Olson, HC
Citation: Ja. Farrow et al., Pregnant adolescents in chemical dependency treatment - Description and outcomes, J SUBST ABU, 16(2), 1999, pp. 157-161
Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: A randomized trial
Authors: Maiman, M Watts, DH Andersen, J Clax, P Merino, M Kendall, MA
Citation: M. Maiman et al., Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: A randomized trial, OBSTET GYN, 94(6), 1999, pp. 954-961
The effects of three nonoxynol-9 preparations on vaginal flora and epithelium
Authors: Watts, DH Rabe, L Krohn, MA Aura, J Hillier, SL
Citation: Dh. Watts et al., The effects of three nonoxynol-9 preparations on vaginal flora and epithelium, J INFEC DIS, 180(2), 1999, pp. 426-437
Lactobacilli and vaginal host defense: Activation of the human immunodeficiency virus type 1 long terminal repeat, cytokine production, and NF-kappa B
Authors: Klebanoff, SJ Watts, DH Mehlin, C Headley, CM
Citation: Sj. Klebanoff et al., Lactobacilli and vaginal host defense: Activation of the human immunodeficiency virus type 1 long terminal repeat, cytokine production, and NF-kappa B, J INFEC DIS, 179(3), 1999, pp. 653-660
1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
Authors: Masur, H Kaplan, JE Holmes, KK Alston, BL Ampel, N Anderson, JR Baker, AC Barr, D Bartlett, JG Bennett, JE Benson, CA Bozzette, SA Chaisson, RE Crumpacker, CS Currier, JS Deyton, L Drew, WL Duncan, WR Eisinger, RW El-Sadr, W Feinberg, J Freedberg, KA Furrer, H Gnann, JW Goldberger, MJ Goldie, S Goosby, EP Gross, PA Hafner, R Havlir, D Hooton, TM Jabs, DA Jacobson, MA Janoff, E Kitahata, M Kovacs, JV Leport, C Levin, MJ Lopez, JC Marco, M Mayers, DL Melnick, DA Mofenson, LM Montaner, JSG Moore, R Neaton, J Nelson, C O'Neill, JF Palefsky, J Pau, A Phair, JP Piscitelli, S Polis, MA Quinn, TC Reiss, P Rimland, D Sears, CL Seeff, L Sepkowitz, KA Slama, TG Sloand, EM Spector, SA Thomas, DL Van Dyke, RB Watts, DH Wheat, LJ Whitcup, SM Williams, P Wright, TC Castro, KG DeCock, KM Dowell, SF Dworkin, MS Dykewicz, C Ellerbrock, T Hajjeh, R Holmberg, S Holtgrave, DR Jaffe, HW Jones, JL Juranek, DD Mast, E Navin, T Pellett, PE Reeves, WC Stewart, JA Villarino, ME Kaplan, JE
Citation: H. Masur et al., 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus, ANN INT MED, 131(11), 1999, pp. 873-908
Vertical transmission of human papillomaviruses - Reply
Authors: Watts, DH Kuypers, J Kiviat, NB
Citation: Dh. Watts et al., Vertical transmission of human papillomaviruses - Reply, AM J OBST G, 180(3), 1999, pp. 775-775
Risultati: 1-14 |